BioSpace News Archive

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its board of directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-40.

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase 2 study of AKCEA-APOCIII-LRx in the treatment of patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease (CVD).

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), today announced that it has secured a $3.5 million revolving demand operating credit facility (the “Facility”) with the Royal Bank of Canada

AmerisourceBergen has enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics provider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver complete support from clinical trials through commercialization.

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it is finalizing its FDA filing for its next generation, advanced ECG analysis software with an expectation to file a 510(k) clearance application with the US FDA by end of February 2020.

Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that the results from its H1 influenza oral tablet vaccine challenge study were published in the Lancet Infectious Diseases, January 21, 2020 and currently available at doi.org/10.1016/S1473-3099(19)30584-5. Topline results had been reported previously.

INHIBITOR Therapeutics, Inc. (OTCQB: INTI), today announced that the company has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate an IND-opening clinical study as a two-part, multi-center, randomized, double-blind, placebo-controlled, Phase 2b clinical trial t

Tangible® Science, an innovator creating a dramatically better contact lens experience for patients and eye care practices, today recapped its 2019 accomplishments and announced the expected launch timing for its new conditioning solution, Tangible® Boost.

Vizuri Health Sciences LLC reports that the American College of Rheumatology, an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.

Frazier Healthcare Partners (“Frazier”) today announced the acquisition of EPTAM Precision Solutions (“EPTAM” or the “Company”) and the appointment of Frazier Operating Partner, Mark Kemp, as CEO.